EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Compound from the Phenylsulfonylpiperazine Class: Evaluation of In Vitro Activity on Luminal Breast Cancer Cells

Fernanda Cardoso da Silva iD, Ana Clara Cassiano Martinho iD, Helen Soares Valença Ferreira, Raoni Pais Siqueira, Vinicius Marques Arruda, Joyce Ferreira da Costa Guerra iD, Maria Laura Dos Reis de Souza, Emanuelly Silva Landin, Celso de Oliveira Rezende Júnior iD, Thaise Gonçalves de Araújo iD

Molecules · 2024

DOI: 10.3390/molecules29184471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Fernanda Cardoso da Silva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Genetics and Biotechnology, Institute of Biotechnology, Universidade Federal de Uberlândia, Patos de Minas 38700-002, MG, Brazil. Hauptthemen laut MEDLINE: Breast Neoplasms, Piperazines, Antineoplastic Agents, Cell Proliferation. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most common cancer in women, and is characterized by its histological and molecular heterogeneity. Luminal BC is an estrogen receptor-positive subtype, with varied clinical courses. Although BC patients are eligible for hormone therapy, both early and late relapses still occur, and thus there is a demand for new cytotoxic and selective treatment strategies for these patients. In the present study, inspired by the structure of phenylsulfonylpiperazine, a series of 20 derivatives were tested in bioassays against MCF7, MDA-MB-231 and MDA-MB-453 BC cells to discover new hit compounds. After 48 h of treatment, 12 derivatives impaired cell viability and presented significant IC50 values against at least one of the tumor lineages. Overall, the luminal BC cell line MCF7 was more sensitive to treatments. Compound 3, (4-(1H-tetrazol-1-yl)phenyl)(4-((4-chlorophenyl)sulfonyl)piperazin-1-yl)methanone, was the most promising, with IC50 = 4.48 μM and selective index (SI) = 35.6 in MCF7 cells. Compound 3 also presented significant antimigratory and antiproliferative activities against luminal BC cells, possibly by affecting the expression of genes involved in the epithelial–mesenchymal transition mechanism, upregulating E-Cadherin transcripts (CDH1). Our findings suggest that phenylsulfonylpiperazine derivatives are potential candidates for the development of new therapies, especially those targeting luminal BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPiperazinesAntineoplastic AgentsCell ProliferationHumansFemaleMCF-7 CellsCell Line, TumorCell SurvivalCell MovementEpithelial-Mesenchymal TransitionStructure-Activity RelationshipDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

breast cancerchemotherapycytotoxicityphenylsulfonylpiperazinesulfonamides

Substanzen

PiperazinesAntineoplastic Agents

Autor:innen und Institutionen

  • Laboratory of Genetics and Biotechnology, Institute of Biotechnology, Universidade Federal de Uberlândia, Patos de Minas 38700-002, MG, Brazil.
  • Laboratory of Drug Candidate Synthesis, Institute of Chemistry, Universidade Federal de Uberlândia, Uberlândia 38400-902, MG, Brazil.
  • Laboratory of Biochemistry, Institute of Biotechnology, Universidade Federal de Uberlândia, Patos de Minas 38700-002, MG, Brazil.
  • Laboratory of Nanobiotechnology Prof. Dr. Luiz Ricardo Goulart Filho, Institute of Biotechnology, Universidade Federal de Uberlândia, Uberlândia 38405-302, MG, Brazil.

ORCID-Profile: Fernanda Cardoso da Silva, Ana Clara Cassiano Martinho, Joyce Ferreira da Costa Guerra, Celso de Oliveira Rezende Júnior, Thaise Gonçalves de Araújo

Förderung

  • Fundação de Amparo à Pesquisa de Minas Gerais
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • National Institute of Science and Technology in Theranostics and Nanobiotechnology - INCT - Teranano. Minas Gerais Research Foundation - Brazil
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and the National Institute of Science and Technology in Theranostics and Nanobiotechnology—…

Zitieren

APA

da Silva, F. C., Martinho, A. C. C., Ferreira, H. S. V., Siqueira, R. P., Arruda, V. M., Guerra, J. F. D. C., de Souza, M. L. D. R., Landin, E. S., Rezende Júnior, C. O., & de Araújo, T. G. (2024). A Novel Compound from the Phenylsulfonylpiperazine Class: Evaluation of In Vitro Activity on Luminal Breast Cancer Cells. Molecules. https://doi.org/10.3390/molecules29184471

Vancouver

da Silva FC, Martinho ACC, Ferreira HSV, Siqueira RP, Arruda VM, Guerra JFDC, et al. A Novel Compound from the Phenylsulfonylpiperazine Class: Evaluation of In Vitro Activity on Luminal Breast Cancer Cells. Molecules. 2024. doi:10.3390/molecules29184471

BibTeX
@article{daSilva2024,
  author = {da Silva, Fernanda Cardoso and Martinho, Ana Clara Cassiano and Ferreira, Helen Soares Valença and Siqueira, Raoni Pais and Arruda, Vinicius Marques and Guerra, Joyce Ferreira da Costa and de Souza, Maria Laura Dos Reis and Landin, Emanuelly Silva and Rezende Júnior, Celso de Oliveira and de Araújo, Thaise Gonçalves},
  title = {A Novel Compound from the Phenylsulfonylpiperazine Class: Evaluation of In Vitro Activity on Luminal Breast Cancer Cells},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29184471}
}
Kostenlos starten →